Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

Discontinued Administration (6 Months a Year) of Growth Hormone to Children With Very Short Stature and Having Suffered From Intrauterine Growth Retardation: Safety and Effect on Growth of Long-term Therapy

This trial is conducted in Europe. The aim of this trial is to assess the safety of long-term growth hormone treatment in growth-retarded children with intrauterine growth retardation (IUGR) enrolled in trial GHRETARD/F/1/F.

Inclusion Criteria:

• Patients born with IUGR enrolled in trial GHRETARD/F/1/F
• Bone age below 14 years in boys and 12 years in girls

Exclusion Criteria:

• Bone age above 14 years in boys and 12 years in girls